About Benitec Biopharma
Benitec Biopharma (NASDAQ:BNTC) is a dynamic biotechnology firm focused on the development of genetic medicines. Benitec's innovative approach leverages its proprietary gene-silencing technology, called DNA-directed RNA interference (ddRNAi), to create therapies aimed at treating chronic and life-threatening diseases. The company's pipeline includes projects targeting conditions such as hepatitis B, age-related macular degeneration, and oculopharyngeal muscular dystrophy, showcasing its commitment to addressing unmet medical needs through groundbreaking research. With a mission to pioneer the next generation of genetic medicines, Benitec strives to improve patient outcomes and alter the course of disease with its cutting-edge technologies and therapies.
Snapshot
Operations
Products and/or services of Benitec Biopharma
- BB-301 for oculopharyngeal muscular dystrophy, a gene-silencing therapy aiming to reduce the production of toxic proteins causing muscle weakness.
- Gene therapy projects targeting chronic and life-threatening conditions, leveraging DNA-directed RNA interference technology.
- BB-103 for hepatitis B, a treatment designed to disrupt the viral replication process.
- Collaborations with academic and biomedical entities to develop innovative gene therapies for various diseases.
- Research on ddRNAi technology, a proprietary platform for developing treatments targeting genetic disorders.
- Development services for third-party gene therapy products, including custom gene-silencing constructs and licensing of proprietary technologies.
Benitec Biopharma executive team
- Dr. Jerel A. Banks M.D., Ph.D.Executive Chairman & CEO
- Ms. Megan Joan Boston B.Com., C.A.CFO, Secretary & Director
- Ms. Sophie MukadamChief Operating Officer
- Dr. Michael GrahamHead of Discovery & Founding Scientist
- Dr. Claudia Kloth Ph.D.Senior Vice President of Manufacturing